The U.S. is expected to maintain the largest share of the market at 65.6 percent. U.S. market revenue is forecasted to increase at a slightly lower CAGR of 3.5 percent from $1.39 billion to $1.78 billion.
The market includes allografts, bone morphogenetic proteins, demineralized bone matrices, synthetic bone substitutes and more.
More Articles on Devices:
Kiva Device for Spinal Fractures Cleared by FDA
Device Companies — 7 Key Notes — Stryker, Orthofix & More
4 Recent Spine & Orthopedic Device Company Expansions
